Microfluidic Production of Drug-Loaded Liposomes | Lab Webinar

Added:

Conventional Bulk Methods and the Scalability Bottlenecks of Microfluidics

While microfluidics offers precise control over liposome size and polydispersity at the benchtop scale, critics point out significant hurdles when transitioning to commercial-scale GMP production. The concept of "scale-independent" manufacturing via microfluidics typically relies on "numbering-up" (parallelizing multiple microchannels). In practice, this approach is highly vulnerable to channel clogging, flow maldistribution, and high fabrication and maintenance costs. Consequently, traditional bulk formulation methods—such as ethanol injection, high-pressure homogenization, and high-shear mixing—remain the industry standards for high-throughput, cost-effective clinical manufacturing. These conventional methods, despite producing slightly wider particle size distributions, avoid the complex fluidic engineering and cleanroom microfabrication overhead associated with massive microfluidic arrays, raising valid questions about whether microfluidics is always the most viable or economical pathway from bench to clinic.

Fundamentals of lipid biochemistry, including phospholipid bilayer structure, amphipathic properties, and liposome self-assembly.
Basic principles of microfluidics, specifically laminar flow, diffusion-dominated mixing, and low Reynolds number hydrodynamics.
Mechanisms of drug encapsulation, specifically the distinction between passive loading and active (remote) loading via transmembrane pH or ion gradients.
Introduction to downstream purification methods, particularly the differences between dead-end filtration and tangential flow filtration (TFF).
Characterization methodologies for lipid nanoparticles, including Dynamic Light Scattering (DLS) for size and polydispersity index (PDI), and chromatography for encapsulation efficiency.
Clinical scale-up strategies and Good Manufacturing Practice (GMP) compliance for nanomedicines transitioning from benchtop to clinical trials.
In vivo pharmacokinetics, biodistribution, and the therapeutic mechanism of pegylated liposomal doxorubicin (e.g., the Enhanced Permeability and Retention (EPR) effect).
Advanced microfluidic chip architectures, such as staggered herringbone mixers or 3D flow-focusing, for high-throughput nanoparticle synthesis.
12.3K views120likes19:25@PrecisionNanoSystemsOriginal Release: 2020-03-10

Microfluidic techniques enable scalable, continuous production of liposomal doxorubicin with high encapsulation efficiency (>90%), where particle size decreases with increasing flow rate ratio but remains stable across different total flow rates, and solvent choice significantly impacts both particle size and drug loading efficiency, with ethanol yielding optimal results comparable to the FDA-approved Doxil formulation.